Key Takeaways

The U.S. Food and Drug Administration has sent over 100 warnings to drugmakers

Hims was flagged for its misleading claims about compounded Ozempic/Wegovy

The FDA says compounded drugs are not FDA-approved and may pose risks

WEDNESDAY, Sept. 17, 2025 (HealthDay News) — Federal health officials are cracking down on telehealth companies’ promotion of unapproved versions of prescription drugs, including popular weight loss medications.

On Tuesday, the U.S. Food and Drug Administration (FDA) released more than 100 warning letters aimed at both drugmakers and online health companies. Among them: Hims & Hers , a telehealth platform that has made a name by selling lower-cost versions of well-known drugs, The Associated Press said.

The agency said Hims crossed the line by te

See Full Page